Experientia

, Volume 44, Issue 2, pp 137–141 | Cite as

Platelet monoamine oxidase B: Use and misuse

  • M. B. H. Youdim
Multi-author Review The Platelet in Pathophysiological Research

Summary

The human platelet in addition to having serotonin (5-HT) receptors, uptake carriers (receptor) and transmitter storage vesicles, primarily possesses mitochondrial monoamine oxidase (MAO) type B. Similar to the major form of MAO in the human brain, this enzyme actively oxidizes A-B and B substrates (tyramine, dopamine, phenylethylamine) as well as the novel secondary amine anticonvulsant, milacemide and dopaminergic neurotoxin, MPTP. 5-HT oxidation is hardly affected by the platelet enzyme and MAO inhibitors have no net effect on its accumulation. MAO-B is selectively inhibited by 1-deprenyl and thus the platelet enzyme may be useful to monitor the anti-Parkinson activity of such drugs, as related to their ability to inhibit brain MAO-B. The oxidation of the anticonvulsant, milacemide, to glycine in vitro and in vivo by MAO-B, may herald new prospects for the development of inert prodrugs capable of being metabolized to neuroactive substances by MAO-B. The plasma levels of their metabolites may be an index of MAO-B activity found in the platelet and brain.

Key words

Monoamine oxidase A and B serotonin phenylethylamine milacemide Parkinson's disease epilepsy anticonvulsant platelet clorgyline and deprenyl 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ashkenazi, R., The structural requirements of phenylethylamines in elicitating the serotonin syndrome, in: Enzymes and Neurotransmitters in Mental Disease, pp. 445–455. Eds E. Usdin, T. L. Sourkes and M. B. H. Youdim. Wiley, Chichester 1980.Google Scholar
  2. 2.
    Banerjee, D. K., Kelner, K., Offut, L., Pollard, H. B., and Youdim, M. B. H., Selective regulation of MAO-A but not B activity in cultured adrenal medullary endothelial cells by steroids. Br. J. Pharmac. Chemother.87 (1986) 67P.Google Scholar
  3. 3.
    Banerjee, D. K., Orenberg, R., Youdim, M. B. H., Heldman, E., and Pollard, H. B., Endothelial cells from bovine adrenal medulla develop capillary-like growth patterns in culture. Proc. Natl. Acad. Sci. USA82 (1985) 4702–4706.PubMedGoogle Scholar
  4. 4.
    Bevan Jones, A. B., Pare, C. M. B., Nicholson Price, K., and Stacey, R. S., Brain amine concentrations after monoamine oxidase inhibitor administration. Br. med. J.i (1972) 17–19.Google Scholar
  5. 5.
    Birkmayer, W., Riederer, P., Ambrozi, L., and Youdim, M. B. H., Implications of combined treatment with Madopar® and 1-deprenil in Parkinson's disease. Lancet1 (1977) 439–444.PubMedGoogle Scholar
  6. 6.
    Braestrup, C., Andersen, H., and Randrup, A., the monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behavior in rats without inhibition of catecholamine metabolite formation. Eur. J. Pharmac.34 (1975) 181–188.Google Scholar
  7. 7.
    Cawthon, R. M., Pintar, J. E., Haseltine, F. P., and Breakefield, X. O., Differences in structure of A and B forms of human monoamine oxidase. J. Neurochem.37 (1981) 363–372.PubMedGoogle Scholar
  8. 8.
    Collins, G. G. S., Sandler, M., Williams, E. D., and Youdim, M. B. H., Multiple forms of human brain mitochondrial monoamine oxidase. Nature, Lond.225 (1970) 817–820.Google Scholar
  9. 9.
    Curtis, D. R., and Johnston, G. A. R., Amino acid transmitters in the mammalian central nervous system. Ergebn. Physiol. Biol. comp. exp. Pharmac.69 (1974) 97–188.Google Scholar
  10. 10.
    Da Prada, M., Picotti, G. B., Kettler, R., and Launay, J. M., Serotonin, histamine, catecholamines and octopamine in blood platelets, in: Platelets: Cellular Response Mechanism and Their Biological Significance, pp. 277–288. Eds A. Rotman, F. A. Meyer, C. Gitler and E. Silberberg. Wiley, Chichester 1980.Google Scholar
  11. 11.
    Davidson, J., Mcleod, M. N., and Blum, R., Acetylation phenotype, platelet monoamine oxidase inhibition and the effectiveness of phenelzine in depression. Am. J. Psychiat.135 (1978) 147–152.Google Scholar
  12. 12.
    Denney, R. M., and Abell, C. W., The genetics of MAO, in: Monoamine Oxidase and Disease, pp. 243–252. Eds K. F. Tipton, P. Dostert and M. Strolin-Benedetti. Academic Press, London 1984.Google Scholar
  13. 13.
    Denney, R. M., Thorpe, L., Wesllund, K., Kochersperger, L. M., and Abell, C. W., Visualization of monoamine oxidase A and B in brain and peripheral tissues with monoclonal antibodies specific for the two forms of the enzyme, in: MPTP: A Parkinson Syndrome Producing Neurotoxin, pp. 645–650. Eds S. Markey, N. Castagnoli and I. J. Kopin. Academic Press, New York 1986.Google Scholar
  14. 14.
    Donelly, C. H., and Murphy, D. L., Monoamine oxidase in man: Enzyme characteristics in platelets, plasma and other human tissues. Adv. Biochem. Psychopharmac.12 (1974) 71–85.Google Scholar
  15. 15.
    Donelly, C. H., Richelson, E., and Murphy, D. L., Properties of monoamine oxidase in mouse neuroblastoma NIE-115 cells. Biochem. Pharmac.25 (1976) 1639–1643.Google Scholar
  16. 16.
    Fowler, C. J., and Strolin-Benedetti, M., The metabolism of dopamine by both forms of monoamine oxidase in the rat brain and its inhibition by cimoxatone. J. Neurochem.40 (1983) 1534–1541.PubMedGoogle Scholar
  17. 17.
    Fowler, C. J., and Tipton, K. F., Deamination of 5-hydroxytryptamine by both forms of monoamine oxidase in the rat brain. J. Neurochem.38 (1982) 733–736.PubMedGoogle Scholar
  18. 18.
    Fowler, C. J., O'Carroll, A. M., and Tipton, K. F., Deamination of dopamine by monoamine oxidase A and B in rat and in man, in: Monoamine Oxidase and Disease, pp. 392–393. Eds K. F. Tipton, P. Dostert, and M. Strolin-Benedetti. Academic Press, London 1984.Google Scholar
  19. 19.
    Fowler, C. J., Tipton, K. F., Mackay, A. V. P., and Youdim, M. B. H., Human platelet monoamine oxidase — A useful enzyme in the study of psychiatric disorders? Neuroscience7 (1982) 1577–1594.PubMedGoogle Scholar
  20. 20.
    Garrick, N., and Murphy, D. L., Differences in selectivity towards norepinephrine compared to serotonin. Biochem. Pharmac.31 (1982) 4061–4067.Google Scholar
  21. 21.
    Grahame-Smith, D. G., et al., Human platelet 5-hydroxytryptamine receptors: Binding of [3H]-lysergic acid diethylamide (LSD). Effects of chronic neuroleptic and antidepressant drug administration. Experientia44 (1987) 142–145.Google Scholar
  22. 22.
    Green, A. R., and Youdim, M. B. H., Effect of monoamine oxidase inhibition by clorgyline deprenyl or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br. J. Pharmac. Chemother.55 (1975) 415–422.Google Scholar
  23. 23.
    Green, A. R., Mitchell, B., Tordoff, A., and Youdim, M. B. H., Evidence of dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br. J. Pharmac. Chemother.60 (1977) 343–348.Google Scholar
  24. 24.
    Hamon, M., Bourgoin, S., and Youdim, M. B. H., Typtophan hydroxylation in the central nervous system, in: Aromatic Amino Acid Hydroxylases and Mental Diseases, pp. 233–298. Ed. M. B. H. Youdim. Wiley, Chichester 1984.Google Scholar
  25. 25.
    Heikkila, R. E., Manzio, L., Cabbat, F. S., and Duvoisin, R. C., Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl 1,2,3,6-tetra hydropyridine by monoamine oxidase inhibitors. Nature311 (1984) 467–469.PubMedGoogle Scholar
  26. 26.
    Johnston, J. P., Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmac.17 (1968) 1285–1297.Google Scholar
  27. 27.
    Kalir, A., Sabbagh, A., and Youdim, M. B. H., Selective acetylenic ‘suicide’ and reversible inhibitors of monoamine oxidase type A and B. Br. J. Pharmac. Chemother.73 (1981) 55–64.Google Scholar
  28. 28.
    Knoll, J., and Magyar, K., Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmac.5 (1972) 393–408.Google Scholar
  29. 29.
    Kochersperger, L. M., Wagnespack, A., Patterson, J. C., Hsieh, C. C. W., Weyler, W., Salach, J. I., and Denney, R. M., Immunological uniqueness of human monoamine oxidase A and B. New evidence from studies with monoclonal antibodies to human monoamine oxidase A. J. Neurosci.5 (1986) 2874–2881.Google Scholar
  30. 30.
    Kuhn, D., Wolf, W., and Youdim, M. B. H., 5-Hydroxytryptamine release in vivo from a cytoplasmic pool: Studies on the 5-HT behavioural syndrome in reserpinized rats. Br. J. Pharmac. Chemother.84 (1985) 121–129.Google Scholar
  31. 31.
    Kuhn, D., Wolf, W., and Youdim, M. B. H., Serotonin neurochemistry revisited: A new look at some old axioms. Neurochem. int.8 (1986) 141–154.Google Scholar
  32. 32.
    Langer, S., and Galzin, A.-M., Studies on the serotonin transporter in platelets. Experientia44 (1987) 127–130.Google Scholar
  33. 33.
    Larsen, J. K., and Rafaelsen, O. J., Long-term treatment of depression with ISO-carboxazide. Acta psychiat. neurol. scand.62 (1980) 456–463.Google Scholar
  34. 34.
    Laubscher, A., and Pletscher, A., Shape change and uptake of 5-hydroxytryptamine in human blood platelets action of neuropsychiatric drugs. Life Sci.24 (1979) 1833–1840.PubMedGoogle Scholar
  35. 35.
    Levitt, P., Pintar, J., and Breakefield, X. O., Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc. natl Acad. Sci. USA79 (1982) 6385–6389.PubMedGoogle Scholar
  36. 36.
    Markey, S. P., Castagnoli, N. Jr. Trevor, A. J., and Kopin, I. J., (Eds), MPTP: A Neurotoxin Producing a Parkinsonian Syndrome. Academic Press, New York 1986.Google Scholar
  37. 37.
    Markey, S. P., Johanssen, J. N., Chiueh, C. C., Burns, R. S., and Herkenham, M. A., Interneuronal generation of a pyrimidium ion metabolite may cause drug-induced Parkinsonism. Nature311 (1984) 464–467.PubMedGoogle Scholar
  38. 38.
    Meldrum, B. S., Drugs acting on amino acid neurotransmitters, in: Myoclonus. Adv. Neurol., vol. 43, pp. 687–706. Eds S. Fahn, C. D. Marsden and M. Van Woert. Raven Press, New York 1986.Google Scholar
  39. 39.
    Mendlewicz, J., and Youdim, M. B. H., Anti-depressant potentiation of 5-hydroxytryptophan byl-deprenyl a MAO type B-inhibitor. J. neural Transm.48 (1978) 279–286.Google Scholar
  40. 40.
    Mendlewicz, J., and Youdim, M. B. H., Anti-depressant potentiation of 5-HTP by 1-deprenyl in affective illness. J. affect. Dis.2 (1980) 137–146.PubMedGoogle Scholar
  41. 41.
    Mendlewicz, J., and Youdim, M. B. H.,l-Deprenil. A selective monoamine oxidase type B inhibitor in the treatment of depression. A double blind evaluation. Br. J. Psychiat.142 (1983) 508–511.Google Scholar
  42. 42.
    O'Carroll, A. M., Fowler, C. J., Phillips, J. P., Tobia, I., and Tipton, K. F., The deamination of dopamine by human brain monoamine oxidase specificity for the two forms in seven brain regions. Arch. Pharmac.322 (1983) 198–202.Google Scholar
  43. 43.
    Oreland, L., The activity of human brain and thrombocyte monoamine oxidase (MAO) in relation to various psychiatric disorders, in: Monoamine Oxidase: Structure, Function and Altered Function, pp. 379–387. Eds T. P. Singer, R. W. Von Korff and D. L. Murphy. Academic Press, New York 1979.Google Scholar
  44. 44.
    Pletscher, A., Platelets as models of monoaminergic neurons, in: Essays in Neurochemistry and Neuropharmacology, vol. 4, pp. 49–101. Eds M. B. H. Youdim, W. Lovenberg, D. F. Sharman and L. Lagnado. Wiley, Chichester 1978.Google Scholar
  45. 45.
    Pletscher, A., and Laubscher, A., Use and limitation of platelets as models for neurons: Amine release and shape change reaction, in: Platelets: Cellular Response Mechanisms and Their Biological Significance, pp. 267–276. Eds A. Rotman, F. A. Meyer, C. Gitler, and A. Silberberg. Wiley, Chichester 1980.Google Scholar
  46. 46.
    Pollard, H. B., Ornberg, R., Levine, M., Kellner, K., Morita, K., Levine, R., Forsberg, E., Brocklehurst, K. W., Duong, L., Lelkes, P. I., Heldman, E., and Youdim, M. B. H., Hormone secretion by exocytosis with emphasis on information from chromaffin cell system. Vitams Horm.42 (1986) 109–194.Google Scholar
  47. 47.
    Raft, D., Davidson, J., Wasik, R., and Mattox, A., Relationship between response to phenelzine and MAO inhibition in a clinical trial of phenelzine amitriptyline and placebo. Neuroendocrinology7 (1981) 122–126.Google Scholar
  48. 48.
    Reynolds, G. P., Riederer, P., Sandler, M., Jellinger, K., and Seeman, D., Amphetamine and phenylethylamine in post-mortem Parkinson's brain after (−) deprenyl administration. J. neural Transm.43 (1978) 271–277.PubMedGoogle Scholar
  49. 49.
    Riederer, P., Youdim, M. B. H., Rausch, W. D., Birkmayer, W., Jellinger, K., and Seemann, D., On the mode of action of 1-deprenyl in human central nervous system. J. neural Transm.43 (1978) 217–226.PubMedGoogle Scholar
  50. 50.
    Riederer, P., and Youdim, M. B. H., Brain monoamine oxidase activity and monoamine metabolism in Parkinson patients treated with 1-deprenyl. J. Neurochem.46 (1986) 1359–1365.PubMedGoogle Scholar
  51. 51.
    Roba, J., Milacemide: A novel anti-convulsant, in: New Anticonvulsant Drugs, pp. 179–190. Eds B. S. Meldrum and R. R. Porter, J. Libbey and Co., London 1986.Google Scholar
  52. 52.
    Salach, J. I., Detmer, K., and Youdim, M. B. H., The reaction of bovine and rat liver monoamine oxidase with (14C)-clorgyline and (14C)-deprenyl. Molec. Pharmac.16 (1979) 234–241.Google Scholar
  53. 53.
    Salach, J. I., Singer, T. P., Yasunobu, K. T., Minamura, N., and Youdim, M. B. H., Cysteinyl flavin in monoamine oxidase from the central nervous system, in: Monoamine Oxidase and Its Inhibition. Ciba Foundation Symposium 39, New Series, pp. 49–60. Elsevier, Amsterdam 1976.Google Scholar
  54. 54.
    Strolin-Benedetti, M., Sontag, N., Boucher, T., and Kan, J. P., Aliphatic amines as MAO substrates in the rat. The effect of selective inhibitors on the deamination ofn-pentylamine, in: Function and Regulation of Monoamine Enzymes, pp. 527–538. Eds E. Usdin, N. Weiner and M. B. H. Youdim. Macmillan, London 1981.Google Scholar
  55. 55.
    Tipton, K. F., Enzymology of monoamine oxidase. Cell Biochem. Funct.4 (1986) 79–87.PubMedGoogle Scholar
  56. 56.
    Tipton, K. F., Dostert, P., and Strolin-Benedetti, M. (Eds), Monoamine Oxidase and Disease. Academic Press, New York 1984.Google Scholar
  57. 57.
    Ungar, A., and J. H. Phillips, Regulation of the adrenal medulla. Physiol. Rev.63 (1983) 787–843.PubMedGoogle Scholar
  58. 58.
    de Varebeke, P. J., Cavalier, R., David-Remacle, M., and Youdim, M. B. H., Conversion of the novel anticonvulsant milacemide to glycine in the brain is mediated by monoamine oxidase B. J. Neurochem. (1987) in press.Google Scholar
  59. 59.
    Walker, W. H., Kearney, E. B., Seng, R. L., and Singer, J. P., The covalentyl-bound flavin of hepatic monoamine oxidase. 2. Identification and properties of cysteinyl riboflavin. Eur. J. Biochem.24 (1971) 328–331.PubMedGoogle Scholar
  60. 60.
    Westlund, K., Denney, R., Kochersperger, L., Rose, I. R., and Abell, C., Distinct monoamine oxidase A and B populations in primate brain. Science230 (1985) 181–183.PubMedGoogle Scholar
  61. 61.
    Wolf, W., Youdim, M. B. H., and Kuhn, D., Does brain 5-HIAA indicate serotonin release or monoamine oxidase activity. Eur. J. Pharmac.109 (1985) 381–387.Google Scholar
  62. 62.
    Youdim, M. B. H., and Ashkenazi, R., Serotonin in Biological Psychiatry. Adv. Biochem. Psychopharmac.34 (1982) 35–60.Google Scholar
  63. 63.
    Youdim, M. B. H., and Finberg, J. P. M., Monoamine oxidase inhibitor antidepressants, in: Psychopharmacology, pp. 38–57. Eds. D. G. Grahame-Smith, A. Hippius and H. Winoker. Excerpta Medica, Amsterdam 1982.Google Scholar
  64. 64.
    Youdim, M. B. H., and Finberg, J. P. M., Monoamine oxidase inhibitors antidepressants, in: Psychopharmacology, pp. 37–71. Eds D. G. Grahame-Smith, A. Hippius and H. Winoker. Excerpta Medica, Amsterdam 1985.Google Scholar
  65. 65.
    Youdim, M. B. H., and Hefez, A., Platelet function and monoamine oxidase activity in psychiatric disorders, in: Platelets: Cellular Response Mechanisms and their Biological Significance, pp. 289–306. Eds A. Rotman, F. A. Meyer, C. Gitler and A. Silberberg. Wiley, Chichester 1980.Google Scholar
  66. 66.
    Youdim, M. B. H., Banerjee, D. K., and Pollard, H. B., Isolated chromaffin cells from adrenal medulla contain primarily monoamine oxidase B. Science224 (1984) 619–621.PubMedGoogle Scholar
  67. 67.
    Youdim, M. B. H., Ben-Harari, R. R., and Bakhle, Y. S., Factors affecting monoamine inactivation in lung, in: Metabolic Aspects of the Lung. Ciba Foundation Symposium, no. 78, pp. 105–128. Eds R. Porter and J. Knight. Elsevier, Amsterdam 1980.Google Scholar
  68. 68.
    Youdim, M. B. H., Finberg, J. P. M., and Tipton, K. F., Monoamine oxidases, in: Catecholamine II. Handbook of Experimental Pharmacology. Eds U. Trendelenburg and N. Weiner. Springer Verlag, Berlin (1987) in press.Google Scholar
  69. 69.
    Youdim, M. B. H., Grahame-Smith, D. G., and Woods, H. F., Some properties of human platelet monoamine oxidase in iron-deficiency anaemia. Clin. Sci. molec. Med.50 (1976) 479–486.Google Scholar
  70. 70.
    Youdim, M. B. H., Collins, G. G. S., Sandler, M., Bevan Jones, A. B., Pare, C. M. B., and Nicholson, W. J., Human brain monoamine oxidase: Multiple forms and selective inhibition. Nature, Lond.236 (1972) 225–228.Google Scholar
  71. 71.
    Youdim, M. B. H., Woods, H. F., Mitchell, B., Grahame-Smith, D. G., and Callender, S., Human platelet monoamine oxidase activity in iron-deficiency anaemia. Clin. Sci. molec. Med.48 (1975) 287–289.Google Scholar
  72. 72.
    Youdim, M. B. H., de Varebeke, J. P., Roba, J., Cavalier, R., and Gilbert, P., Formation of glycine form the novel anticonvulsant milacemide is mediated by brain monoamine oxidase B, in: Advances in Epilepsy, Ed. H. Manleis. Raven Press, New York (1987) in press.Google Scholar

Copyright information

© Birkhäuser Verlag 1988

Authors and Affiliations

  • M. B. H. Youdim
    • 1
    • 2
  1. 1.Rappaport Family Research Institute, Faculty of MedicineTechnionHaifa(Israel)
  2. 2.Department of Pharmacology, Faculty of MedicineTechnionHaifa(Israel)

Personalised recommendations